SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (255)4/4/2001 11:57:22 AM
From: tuck  Respond to of 395
 
I'm no expert, but it seems the trial design inadvertently led them to miss their primary endpoint. They are only barely getting significance on the parental observations, getting none on CARS, a primary endpoint. In my humble opinion, the best case scenario is that they're going to have do some extra clinical work costing time and money on this compound. The subset analysis trick is OK only if they really can get some some pharmacogenomic mileage out of it.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News